Tesamorelin + Ipamorelin - Blend

Tesamorelin + Ipamorelin – Blend

$120.00

The Tesamorelin + Ipamorelin blend brings together two peptide compounds commonly utilized in endocrine and metabolic research. Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH), while Ipamorelin is a selective ghrelin receptor agonist. When studied together, they offer a dual mechanism of action for stimulating endogenous growth hormone (GH) secretion in laboratory settings.

Tesamorelin exhibits high specificity for GHRH receptors and is known for its stability and receptor affinity in experimental models. Ipamorelin complements this by acting on the ghrelin (GHS-R1a) receptor to promote additional GH secretion without significantly impacting other hormones such as prolactin or cortisol. This dual-action design makes the blend a versatile research tool for exploring the interactions between the hypothalamic-pituitary axis, hormone feedback loops, and GH-mediated cellular responses.

0% 1 - 4 $120.00
10% 5 - 9 $108.00
20% 10 + $96.00
  • Free shipping on orders over $200
  • Discounts: Calculated in cart.

Description

The Tesamorelin + Ipamorelin blend is a scientifically designed combination of two potent growth hormone secretagogues. This formulation is tailored for researchers investigating endocrine signaling, GH secretion, and cellular metabolism. The peptides are carefully paired to support in-depth experimental analysis of hormonal interactions in vitro and in vivo.

Tesamorelin is a stabilized analog of endogenous GHRH. It functions by binding to GHRH receptors in the anterior pituitary, initiating the release of GH in a pulsatile pattern. Due to its enhanced stability and receptor-binding characteristics, Tesamorelin has been widely researched in models involving metabolic function, adipocyte signaling, and lipid regulation. Its ability to trigger IGF-1 production in GH-dependent pathways has also made it a subject of interest in regenerative and aging-related cellular studies.

Ipamorelin complements Tesamorelin by acting as a ghrelin mimetic. As a highly selective GHS-R1a receptor agonist, Ipamorelin induces GH release without significantly impacting ACTH, prolactin, or cortisol levels—an advantage over older secretagogues. This selectivity makes it particularly useful for dissecting the role of ghrelin-receptor activity within the broader endocrine system. Its clean receptor profile minimizes off-target effects, providing clearer insights into GH axis dynamics.

When used together, these peptides provide a potent research tool capable of producing both immediate and sustained GH responses. Tesamorelin’s action on GHRH receptors ensures longer-acting hormonal stimulation, while Ipamorelin delivers a rapid but clean pulse of GH activity. This dual-action blend enables more flexible and detailed study designs, including the analysis of dose-response relationships, receptor crosstalk, and circadian hormonal fluctuations.

Product Data

  • Blend Components:

    • Tesamorelin – 5 mg

    • Ipamorelin – 5 mg

  • CAS Numbers:

    • Tesamorelin: 218949-48-5

    • Ipamorelin: 170851-70-4

  • Molecular Formulas:

    • Tesamorelin: C221H366N72O67S

    • Ipamorelin: C49H74N14O10

  • Molecular Weights:

    • Tesamorelin: ~5135.89 g/mol

    • Ipamorelin: ~878.03 g/mol

Research

The Tesamorelin + Ipamorelin blend offers researchers a model system for investigating the physiological and cellular outcomes of enhanced GH secretion through dual-pathway stimulation. Tesamorelin activates the GHRH receptor in the pituitary, while Ipamorelin targets the ghrelin receptor—two distinct but complementary mechanisms.

Tesamorelin has been shown in animal and in vitro studies to stimulate the release of endogenous GH in a predictable, dose-dependent manner. Due to its resistance to enzymatic degradation, Tesamorelin can maintain activity over longer durations, making it suitable for studies on long-term GH stimulation and its systemic effects, including IGF-1 upregulation, lipid metabolism, and tissue remodeling.

Ipamorelin, in contrast, has a shorter half-life but exhibits high selectivity for the ghrelin receptor. Its minimal impact on cortisol, ACTH, or prolactin has made it a preferred candidate for studying isolated GH release. This precision allows for better control over experimental variables and is particularly useful in dissecting downstream GH signaling without interference from other hormonal cascades.

In combination, researchers have observed that Tesamorelin can establish a baseline of prolonged GH stimulation, while Ipamorelin enhances peak GH levels shortly after administration. This synergy may provide valuable data for modeling circadian rhythms, feedback inhibition, and GH pulse patterns. The blend’s dual mechanism allows for investigations into how different receptor pathways interact to modulate pituitary activity and GH dynamics.

Moreover, the use of both peptides together may illuminate complex biological processes such as insulin sensitivity, adipocyte regulation, and anabolic signaling, particularly in long-term cellular and animal studies. However, it’s important to note that all findings are currently limited to preclinical models, and further validation is required.

Related products

  • PT-141 Buy Now

    PT-141

     $55.00 – $65.00 Buy Now This product has multiple variants. The options may be chosen on the product page
  • MOTS-c Buy Now

    MOTS-c

     $110.00 – $180.00 Buy Now This product has multiple variants. The options may be chosen on the product page
  • AOD-9604 Buy Now

    AOD-9604

     $65.00 – $120.00 Buy Now This product has multiple variants. The options may be chosen on the product page
Shopping Cart
Scroll to Top
0